Bone repair assessment of critical size defects in rats treated with mineralized bovine bone (Bio-Oss®) and photobiomodulation therapy: a histomorphometric and immunohistochemical study

• Published in: Lasers in medical science 2021-09, Vol.36 (7), p.1515-1525
• Main Authors: Torquato, Letícia Cavassini, Suárez, Eduardo Antonio Chelin, Bernardo, Daniella Viscensotto, Pinto, Isis Luzcybel Ribeiro, Mantovani, Ludmilla Oliveira, Silva, Thiago Igor Lemes, Jardini, Maria Aparecida Neves, Santamaria, Mauro Pedrine, De Marco, Andrea Carvalho
• Format: Article
• Language: English
• Subjects: Acid phosphatase; Acid phosphatase (tartrate-resistant); Acid resistance; Aluminum; Analgesics; Animals; Biomedical materials; Blood clots; Blood coagulation; Bone healing; Bone matrix; Calvaria; Cattle; Cytochrome; Defects; Dentistry; Fibroblasts; Flux density; Immunohistochemistry; Lasers; Ligands; Light therapy; Medicine; Medicine & Public Health; Optical Devices; Optics; Original Article; Osteoprotegerin; Photonics; Quantum Optics; Science; Skin & tissue grafts; Surgery; TRANCE protein; Variance analysis
• ISSN: 0268-8921; 1435-604X
• DOI: 10.1007/s10103-020-03234-5

This study aimed to investigate the effects of administering photobiomodulation therapy (PBM) with bovine bone matrix on critical size defects in rats. Seventy-two adult male rats (albinus, Wistar), 90 days old, were used. Defect of 5 mm in diameter was made in their calvaria. The animals were divided into 4 groups: C-blood clot, B-Bio-Oss®, L-PBM, B+L-Bio-Oss®+PBM. Each group has been subdivided into 07, 30, and 60 days of observation. For PBM, a low GaAlAs energy of 660 nm was irradiated, total energy density of 45 J/cm 2 . PBM was conducted in a trans-surgical form once only. For immunohistochemistry, a semi-quantitative analysis was made of expression of osteoprotegerin (OPG), nuclear kappa B-factor ligand receptor activator (RANKL), and tartrate-resistant acid phosphatase (TRAP). All histomorphometric data were statistically analyzed by ANOVA and Tukey test, significance level of 5%. The groups that showed the highest proportion of neoformation were L (0.39% ± 0.13) and C (0.37% ± 0.97), but groups B and B + L had larger defect size ( C -1.75 mm 2  ± 0.40, B -3.02 mm 2  ± 0.63, L -2.45 mm 2  ± 0.53, B + L -3.23 mm 2  ± 1.01). In immunohistochemistry, groups B and B + L had higher immunostaining scores for OPG and RANKL at 60 days, and TRAP immunostaining increased in all groups at 30 days, but group L was the only one to present specimens with score 0. Although, at 60 days, groups L and C presented the highest proportion of bone neoformation, at 30 days group B + L had more than twice as much bone neoformation as group B , the choice of treatment application should depend on the aim of the treatment.